Porton Pharma Solutions Signed Strategic Partnership InnoStar

Porton Pharma SolutionsLtd. ("Porton") announced a strategic partnership with Shanghai InnoStar Bio-tech Co., Ltd. ("InnoStar") in Shanghai. The distinguished signing ceremony was attended by Mr. Ju Nianfeng, Chairman and CEO of Porton; Dr. Chang Yan, President of InnoStar; Ms. Pi Wei, Deputy General Manager of Porton; Ms. Fan Meng, Deputy General Manager of the Sales & Marketing Center, Dr. Fang Xin, Senior Director of Non-clinicalPharmacology BU at InnoStar, and Ms. Zhao Jie, Marketing Associate Director at InnoStar.

At today's signing ceremony, Mr. Ju Nianfeng, Chairman and CEO of Porton, emphasized the company's commitment to its mission of "Enabling the public’s early access to good medicines" by maintaining a customer-centric approach and providing innovative, reliable global CDMO solutions. Our services have expanded from small molecule drugs to include new modalities such as peptides, oligonucleotide drugs,  conjugated drugs and advanced therapy medicinal. Through technological innovation and a commitment to open, win-win collaborations, we continue to advance the pharmaceutical industry. The collaboration with InnoStar marks a significant step forward in our pursuit of resource sharing and model innovation. InnoStar's extensive experience in non-clinical research services for innovative drugs,combined with Porton's expertise and resources in the CDMO field, will enhance our service capabilities and efficiency, accelerate the drug development process, and create greater value and opportunities for our clients. Furthermore, this partnership will strengthen our presence in the global market and guide us to a new stage of development.